Sofinnova Investments, Inc. Zymeworks Inc. Transaction History

Sofinnova Investments, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$6.0 - $16.98 $2.36 Million - $6.67 Million	-392,712 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.19 - $29.33 $272,007 - $525,212	-17,907 Reduced 4.36%	392,712 $6.44 Million
Q3 2021 Nov 15, 2021	BUY	$27.35 - $37.28 $11.2 Million - $15.3 Million	410,619 New	410,619 $11.9 Million
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $5.94 Million - $8.35 Million	-151,902 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$29.21 - $46.58 $4.32 Million - $6.89 Million	-147,832 Reduced 49.32%	151,902 $7.08 Million
Q2 2020 Aug 13, 2020	BUY	$33.67 - $40.0 $8.41 Million - $9.99 Million	249,745 Added 499.6%	299,734 $10.8 Million
Q1 2020 May 13, 2020	SELL	$24.28 - $49.8 $1.4 Million - $2.87 Million	-57,563 Reduced 53.52%	49,989 $1.77 Million
Q4 2019 Feb 14, 2020	SELL	$24.84 - $45.46 $2.01 Million - $3.68 Million	-80,886 Reduced 42.92%	107,552 $4.89 Million
Q3 2019 Nov 14, 2019	BUY	$22.78 - $29.08 $8,679 - $11,079	381 Added 0.2%	188,438 $4.67 Million
Q2 2019 Aug 13, 2019	BUY	$15.0 - $22.49 $2.82 Million - $4.23 Million	188,057 New	188,057 $4.14 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $881M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.